skip to content

Clinical Trials

MainTitle

HIP: HIV Intervention for Providers

This study has been completed
Sponsor
Centers for Disease Control and Prevention


Information provided by (Responsible Party)
Centers for Disease Control and Prevention
ClinicalTrials.gov Identifier
NCT00164398

First received: September 9, 2005
Last updated: September 10, 2012
Last Verified: September 2012
History of Changes
Purpose

Purpose

The purpose is to encourage Provider participants to evaluate high risk HIV transmission behaviors and offer prevention messages to their HIV+ patients which will, in turn, reduce rates of unprotected anal and/or vaginal sex with partners of known HIV sero-negativity or unknown HIV serostatus. It is hypothesized that patients of providers participating in the HIP intervention will report higher reduction in sexual risk practices, when compared to the patients of the providers who were randomized into the control condition.

Condition Intervention Phase
HIV Infections

Behavioral : HIP: HIV Intervention for Providers
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: HIP: HIV Intervention for Providers

Further study details as provided by Centers for Disease Control and Prevention:

Primary Outcome Measures

  • Self-reported, unprotected (without condoms) anal or vaginal sex with HIV-negative and unknown-status persons.

Enrollment: 50
Study Start Date: June 2004
Study Completion Date: September 2008
Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)

Eligibility

Eligibility

Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: Yes  

Criteria

Inclusion Criteria:

  • Provider participants: (1) licensed MD, NP or PA on staff at the participating
institution; (2) has a minimum panel of 5 HIV+ patients; (3) sees patients at least one-half day per week in the clinical setting; (4) is willing to participate in all intervention training sessions; and (5) is willing and able to provide full informed consent.
HIV+ patient participants:(1) report at least 1 encounter of unprotected anal or vaginal sex with known HIV- or unknown serostatus partner in the preceding six months; (2) patient's Primary Provider is enrolled as a participant in the study; (3) age 18 years or older; and (4) willing and able to provide informed consent.

Exclusion Criteria:

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00164398

Locations

United States, California
University of California San Francisco - CAPS
San Francisco, California, United States, 94105

Sponsors and Collaborators

Centers for Disease Control and Prevention

Investigators

Principal Investigator: Dogan Eroglu, PhD. Centers for Disease Control and Prevention
More Information

More Information


Responsible Party: Centers for Disease Control and Prevention  
ClinicalTrials.gov Identifier: NCT00164398   History of Changes  
Other Study ID Numbers: CDC-NCHSTP-3986  
  CCR 920974  
Study First Received: September 9, 2005  
Last Updated: September 10, 2012  

Keywords provided by Centers for Disease Control and Prevention:

HIV

Additional relevant MeSH terms:
HIV Infections

ClinicalTrials.gov processed this data on October 20, 2017
This information is provided by ClinicalTrials.gov.